EUCTR2009-017428-17-IT进行中（未招募）不适用
A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma - Vecti-BI
AZIENDA OSPEDALIERA ORDINE MAURIZIANO0 个研究点开始时间: 2010年2月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Histologically or cytologically documented surgically unresectable or metastatic biliary tract adenocarcinoma (KRAS wild-type); ? Documented KRAS status either on primary tumor or metastasis. ? ECOG PS of 0, 1 or 2 ? Extimated life expectancy of at least 3 months. ? Adequate bone marrow, hepatic, and renal function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Any previous chemotherapy or target therapy. ? Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol. ? Coexisting malignancies, except for basal or squamous cell carcinoma of the skin or other solid tumors curatively treated with no evidence of disease for ≥ 3 years.
研究者
相似试验
进行中（未招募）
1 期
An Open-label Phase II Clinical trial of Panitumumab in Combination with Irinotecan for Patients with Advanced Metastatic Colorectal Cancer without KRAS mutation (Wild type) in third line chemotherapy (Patients pretreated with FOLFOX or XELOX ± bevacizumab and irinotecan alone or FOLFIRI or CAPIRI ± bevacizumab) - PIMABIEUCTR2007-004806-28-FRGERCOR69
进行中（未招募）
不适用
An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer (Voxel-Study). - Voxel-StudyEUCTR2007-004866-42-DEAIO-Studien-gGmbH
进行中（未招募）
不适用
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal CancerPatients with metastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006739-36-SEAmgen Inc150
进行中（未招募）
不适用
A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal CancerPatients with metastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2006-006739-36-ATAmgen Inc150
进行中（未招募）
1 期
A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal CancerEUCTR2006-006739-36-FRAmgen Inc150